Home/MapLight Therapeutics/Christopher Kroeger
CK

Christopher Kroeger

Chief Executive Officer, Founder, Board Member

MapLight Therapeutics

MapLight Therapeutics Pipeline

DrugIndicationPhase
ML-007Schizophrenia (negative symptoms)Phase 2
ML-004Autism Spectrum Disorder (ASD)Phase 1
UndisclosedParkinson's DiseasePreclinical